Activation, Apathy, Anergy and Apoptosis
激活、冷漠、无反应和细胞凋亡
基本信息
- 批准号:6691033
- 负责人:
- 金额:$ 34.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-12-01 至 2006-12-31
- 项目状态:已结题
- 来源:
- 关键词:B lymphocyteCD28 moleculeCD40 moleculeanergyapoptosisbusulfancell adhesion moleculescellular immunitycytotoxic T lymphocytedrug interactionsembryonic stem cellhelper T lymphocytehematopoietic stem cellshematopoietic tissue transplantationhomologous transplantationhumoral immunityimmunoregulationimmunosuppressivelaboratory mouseleukocyte activation /transformationstem cell transplantationtissue /cell culturetissue mosaicismtransplant rejectiontransplantation immunology
项目摘要
DESCRIPTION (provided by applicant): Transplantation has emerged as the
preferred method of treatment for many forms of end-stage organ failure. While
short-term results have improved long-term outcomes remain inadequate. To
maintain their allogralts, patients must rigidly adhere to life-long treatment
regimens using costly immunosuppressive agents that dramatically increase the
risks of cardiovascular disease, infections and malignancies. The development
of strategies to promote the acceptance of allogeneic tissues without the need
for chromic immunosupression could not only reduce the risk of these
life-threatening complications, but also greatly expand the application of
organ, tissue and cellular transplantation for diseases such as the
hemoglobinopathies and genetic irnmunodeficiencies, Type I diabetes, and
possibly other autoimmune diseases.
We have developed a novel non-myelosuppressive protocol using anti-CD4OL and
CTLA4-Ig to permit the induction of titratable levels of.
In this proposal we will explore the use of alternative immunomodulatory
strategies to facilitate the development of chimerism and tolerance, study the
interactions of conventional immunosuppressive agents with the tolerance
induction approach, explore the mechanisms involved in tolerance maintenance,
define the effects of tolerance induction on immunologic memory and study the
use of stem cells as alternatives to primary bone marrow preparation.
描述(申请人提供):移植已成为
多种终末期器官衰竭的首选治疗方法。而当
短期结果有所改善,但长期结果仍然不足。至
保持同种异体,患者必须严格坚持终身治疗
使用昂贵的免疫抑制剂的方案显著增加了
心血管疾病、感染和恶性肿瘤的风险。最新进展
促进接受同种异体组织而不需要的策略
因为铬免疫抑制不仅可以降低这些疾病的风险
危及生命的并发症,也大大扩展了其应用范围
器官、组织和细胞移植治疗疾病,如
血红蛋白疾病和遗传免疫缺陷、I型糖尿病和
可能是其他自身免疫性疾病。
我们已经开发了一种新的非骨髓抑制方案,使用抗CD4OL和
CTLA4-Ig允许诱导可滴定水平的。
在这项提案中,我们将探索替代免疫调节剂的使用
促进嵌合体和宽容发展的战略,研究
常规免疫抑制剂与耐受性的相互作用
归纳方法,探索耐受性维持的机制,
明确耐受诱导对免疫记忆的影响,并研究
使用干细胞作为初级骨髓准备的替代品。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTIAN P LARSEN其他文献
CHRISTIAN P LARSEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTIAN P LARSEN', 18)}}的其他基金
Third Generation Costimulation Blockade-Based Tolerance Strategies
第三代基于共刺激封锁的耐受策略
- 批准号:
8705983 - 财政年份:2014
- 资助金额:
$ 34.2万 - 项目类别:
TRANSLATIONAL STRATEGIES FOR PANCREATIC ISLET XENOTRANSPLANTATION IN NHP
NHP 胰岛异种移植的翻译策略
- 批准号:
8357464 - 财政年份:2011
- 资助金额:
$ 34.2万 - 项目类别:
OPTIMIZING IMMUNOTHERAPY FOR ALLOGENEIC ISLET TRANSPLANTATION IN NHP
优化 NHP 异体胰岛移植的免疫治疗
- 批准号:
8357444 - 财政年份:2011
- 资助金额:
$ 34.2万 - 项目类别:
TRANSLATIONAL STRATEGIES FOR PANCREATIC ISLET XENOTRANSPLANTATION IN NHP
NHP 胰岛异种移植的翻译策略
- 批准号:
8172418 - 财政年份:2010
- 资助金额:
$ 34.2万 - 项目类别: